

different from the review [by the Food and Drug Administration (FDA)] if the same enzyme were intended for use as a thrombolytic agent administered intravenously to patients.

We are convinced that protection of human health and the environment, stimulation of industries using new biotechnology, and assurance of safety of products are mutually compatible. The FDA's record of having approved more than 150 products (including in recent weeks the first interferons and a monoclonal antibody that treats acute renal transplant rejection) that use recombinant DNA or hybridoma techniques in their manufacture is evidence of this conviction.

However, government cannot perform regulatory oversight of scientific and commercial endeavors in a vacuum. We require the advice and criticism of academics and of the public. And while we welcome such commentary as Koshland's in *Science*, there are alternatives to effecting better regulation. The most direct is to analyze and comment on the scientific assumptions in statements of policy, and we urge individual scientists and professional organizations to make the required investment in time and energy to do so. The FDA's last statement of

policy on biotechnology elicited a dismal response: a mere 34 official comments. Can that really be all the interest there is in the scientific and regulatory approaches of a major regulatory agency—with responsibility for products accounting for 25 cents of every consumer dollar—to important new technologies?

In addition, public education via lectures and articles directed at nonspecialists, while less direct, is a worthy investment.

Perhaps there was appropriate but unintended irony in Koshland's metaphor of "one gene—one enzyme," which is not an invariant principle. It is now known that certain messenger RNA precursors can be spliced in alternative ways, such that a single primary messenger RNA transcript may ultimately yield two or more very different polypeptides. Likewise, "one license—one hearing" can be a useful, although not universally applicable, model.

HENRY I. MILLER
FRANK E. YOUNG

*Food and Drug Administration,
Rockville, MD 20857*

REFERENCES

1. *Fed. Regist.* 51, 23301 (26 June 1986).

Response: The Biotechnology Science Coordinating Committee appears to be an excellent approximation of the simplicity and responsibility that were advocated in my editorial. I do not think the lack of letters indicates lack of interest but perhaps a past experience of scientists having suggestions fall on deaf ears. Miller and Young deserve great credit for their good solution to a difficult problem and for a receptiveness that will encourage responses.


I hope that Washington bureaucracy does not get as complex as gene expression. If it does, we may have to extend the adage "Ontogeny recapitulates phylogeny" to "Sociology recapitulates enzymology."

—DANIEL E. KOSHLAND, JR.

Erratum: In the article "Mathematicians recognize major discoveries" by Gina Kolata (Research News, 15 Aug., p. 722), Fields Medal winner Michael Freedman was incorrectly described as being a member of the University of Southern California faculty. Freedman is Charles Lee Powell Professor of Mathematics at the University of California, San Diego. In addition, several names in the article were spelled incorrectly. Field's should have been Fields, Nevalinna and Navanlinna should have been Nevanlinna, Kirky should have been Kirby, Atiyah should have been Atiyah, and Strasen should have been Strassen.

Patented Gene Transfer Technology with Proven Success: Applicable to all Biological Systems

BAEKON2000 Advanced Gene Transfer System



PRECISELY CONTROLLABLE
PARAMETERS: Amplitude,
Number of Pulses, Burst Time,
Cycle, and Intensity of
Turbulence.

CONSISTENT QUALITY RESULTS
TIME AFTER TIME.

Unique merits of BAEKON2000

- STERILITY by the use of a sterile disposable receptacle;
- TWO modes of operation: Non-contact and Contact;
- CONTINUOUS output of electric discharges;
- Virtually NO limit in species and number of cells and DNA;
- CONTROLLED turning and mixing of gene-cell mixture DURING transfer.

Our clients are leading scientists in the area of animal, plant and bacterial biotechnology.

BAEKON2000: THE OPTIMAL SOLUTION!

BAEKON, INC.

18866 Allendale Avenue, Saratoga, CA 95070
(408) 741-0404

Complete details upon inquiry.

BURN YOUR REFERENCE CARDS!

REF-11™


Computerizes your REFERENCES
and prepares your BIBLIOGRAPHIES

- ☐ Maintains a data base of references
- ☐ Searches for any combination of authors, years of publication, reference title (or any words in the title), and topics covered by the reference
- ☐ Formats bibliographies exactly as you want them
- ☐ Alphabetizes references
- ☐ Abbreviates journal titles
- ☐ Runs on any video terminal and printer
- ☐ Menu driven dialogue
- ☐ Compact storage format
- ☐ 20 lines of comments for each reference

IBM PC/XT/AT, MS-DOS, CP/M 80 . . . **\$195⁰⁰**

RT-11, TSX-Plus, RSX-11, P/OS **\$250⁰⁰**

VAX/VMS (native mode) **\$350⁰⁰**



ANY
MANUAL **\$15⁰⁰**

ANY
MANUAL & DEMO **\$20⁰⁰**

322 Prospect Ave., Hartford, CT 06106
(203) 247-8500

Connecticut residents add 7½% sales tax.

Circle No. 97 on Readers' Service Card

Circle No. 13 on Readers' Service Card